Migrakind (Sumatriptan)

Sumatriptan, the active ingredient in Migrakind, is a Triptan (selective 5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults. By targeting cranial blood vessels and neurogenic inflammation, it helps relieve migraine pain and associated symptoms such as nausea, photophobia, and phonophobia.

GNH USA supplies Migrakind as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sumatriptan is a selective 5‑HT1B/1D receptor agonist used within the migraine treatment pathway.

Migraine without aura: provides rapid relief of headache and associated symptoms when taken at the onset of an attack. Migraine with aura: reduces headache severity when administered after aura symptoms begin. Acute migraine attack: aborts the attack and alleviates associated nausea, photophobia, and phonophobia when taken early.

Common Side Effects: - Chest tightness or pressure - Tingling or numbness in fingers or toes - Nausea or stomach discomfort - Dizziness or light‑headed feeling - Flushing or warmth sensation - Dry mouth Serious or Rare Side Effects: - Serotonin syndrome, especially with other serotonergic agents - Coronary vasospasm leading to chest pain - Ischemic cardiac events in susceptible patients - Severe allergic reactions such as anaphylaxis - Stroke or transient ischemic attack - Persistent hypertension

Before prescribing Migrakind, clinicians should consider the following precautions: - Cardiovascular disease: avoid use in patients with uncontrolled coronary artery disease. - History of stroke or transient ischemic attack: assess risk before initiating therapy. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Pediatric use: safety and efficacy have not been established in children. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Sumatriptan may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Ergot alkaloids: combined use can cause severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: heightened potential for serotonin toxicity.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sumatriptan plasma concentrations. - CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic effectiveness.